Organon & Co | OGN - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celltrion KRW 218.61M 162.21K 2025-12
Cspc Pharmaceutical CNY 11.52B 3.7M 2025-12
Deva Holding AS TRY 200.02M 0 2023-09
Dianthus Therapeutics USD 43.22M 368.53K 2025-12
Divis Laboratories Ltd INR 265.47M 0 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Kangmei Pharma CNY 13.83B 0 2026-03
Knight Therapeutics CAD 99.68M 24.66K 2025-09
Laboratorios Farma EUR 51.82M 1.55M 2023-12
Malin Corporation EUR 200K 0 2024-12
Medical Developments International AUD 112.66M 2.35M 2025-12
Merck USD 2.47B 12.72M 2025-12
Neuren Pharmaceuticals AUD 126.64M 38.63M 2025-12
Novartis USD 1.91B 10.64M 2025-12
Organigram Holdings CAD 135.13M 671.75K 2025-12
Organon & Co USD 260.32M 333K 2025-12
Ovoca Bio EUR 29.49M 18.43M 2025-06
Pharma Mar EUR 17.36M 0 2026-03
Qiagen NV USD 216.56M 284.67K 2025-12
Sartorius EUR 69.05M 0 2026-03
Sino Biopharmaceutical CNY 17.89B 30.5M 2025-06
Tilray USD 116.52M 5.01M 2025-09
Zealand Pharma A/S 70.61M 319.68K 2025-12